Chemomab Therapeutics Ltd. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
Chemomab Therapeutics Ltd. (CMMB) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $374.00 thousand as of 2025-12-31, per its 20-F filed 2026-03-23.
Financial Statements › Notes › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-23
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $374.00K.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $351.00K.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.16M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.77M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed |
|---|---|---|
| 2025-12-31 | $374.00K 20-F · filed 2026-03-23 | |
| 2024-12-31 | $351.00K 20-F · filed 2026-03-23 | |
| 2023-12-31 | $1.16M 20-F · filed 2025-04-04 | |
| 2022-12-31 | $1.77M 20-F · filed 2025-04-04 | |
| 2021-12-31 | $1.15M 20-F · filed 2024-03-28 | |
| 2020-12-31 | $57.00K 10-K · filed 2022-03-30 | $900.00K 10-K · filed 2021-03-09 |
| 2019-12-31 | $890.00K 10-K · filed 2021-03-09 | |
| 2018-12-31 | $717.00K 10-K · filed 2020-03-17 |